Literature DB >> 35788732

Domains of Structured Oral Anticancer Medication Programs: A Scoping Review.

Kapeena Sivakumaran1, Pamela K Ginex2, Haya Waseem1, Sarah M Belcher3, Sarah Lagler-Clark1, Kristine B LeFebvre2, Nicole Palmer, Tejanth Pasumarthi1, Rebecca L Morgan4.   

Abstract

PROBLEM IDENTIFICATION: An interprofessional approach is necessary to support the multifactorial process of patient adherence to oral anticancer medications (OAMs). This scoping review aims to identify structured OAM programs in published literature, identify components within studies, and propose a framework for institutions developing or maintaining OAM programs. LITERATURE SEARCH: Embase®, PubMed®, and CINAHL® databases were searched for studies published between January 2000 and April 2021. DATA EVALUATION: Two reviewers screened studies and extracted data. Characteristics and specific domains of the OAM programs were captured. Key components of the programs were identified, and a framework was created to guide program development. SYNTHESIS: Components identified among the 21 studies were education; counseling; follow-up; dedicated clinician contact; adverse event and toxicity monitoring; adherence monitoring; drug procurement, delivery, and supply; patient- and system-level cost reduction; information technology; and risk assessment. IMPLICATIONS FOR RESEARCH: Based on the findings, a framework for building and evaluating OAM adherence programs is proposed. Future studies should evaluate the reliability and validity of this framework because further testing may lead to the development of additional components.

Entities:  

Keywords:  medication adherence; nursing; oncology care; oral anticancer medication; scoping review

Mesh:

Substances:

Year:  2022        PMID: 35788732      PMCID: PMC9303043          DOI: 10.1188/22.ONF.296-306

Source DB:  PubMed          Journal:  Oncol Nurs Forum        ISSN: 0190-535X            Impact factor:   1.803


  38 in total

1.  Improved Adherence Rates and Clinical Outcomes of an Integrated, Closed-Loop, Pharmacist-Led Oral Chemotherapy Management Program.

Authors:  Benyam Muluneh; Molly Schneider; Aimee Faso; Lindsey Amerine; Rowell Daniels; Brett Crisp; John Valgus; Scott Savage
Journal:  J Oncol Pract       Date:  2018-05-25       Impact factor: 3.840

2.  2016 Updated American Society of Clinical Oncology/Oncology Nursing Society Chemotherapy Administration Safety Standards, Including Standards for Pediatric Oncology

Authors:  Michael Neuss; Terry Gilmore; Kristin Belderson; Amy Billett; Tara Conti-Kalchik; Brittany Harvet; Carolyn Hendricks; Kristine LeFebvre; Pamela Mangu; Kristen McNiff; MiKaela Olsen; Lisa Schulmeister; Anne Von Gehr; Martha Polovich
Journal:  Oncol Nurs Forum       Date:  2017-01-06       Impact factor: 2.172

3.  Implementation of a pharmaceutical care programme for patients receiving new molecular-targeted agents in a clinical trial unit.

Authors:  G Riu; L Gaba; I Victoria; G Molas; F do Pazo; B Gómez; N Creus; L Vidal
Journal:  Eur J Cancer Care (Engl)       Date:  2016-01-20       Impact factor: 2.520

4.  Impact of an integrated oral chemotherapy program on patient adherence.

Authors:  Katherine P Morgan; Benyam Muluneh; Allison M Deal; Lindsey B Amerine
Journal:  J Oncol Pharm Pract       Date:  2017-04-05       Impact factor: 1.809

5.  2013 updated American Society of Clinical Oncology/Oncology Nursing Society chemotherapy administration safety standards including standards for the safe administration and management of oral chemotherapy.

Authors:  Michael N Neuss; Martha Polovich; Kristen McNiff; Peg Esper; Terry R Gilmore; Kristine B LeFebvre; Lisa Schulmeister; Joseph O Jacobson
Journal:  J Oncol Pract       Date:  2013-03       Impact factor: 3.840

6.  Adherence to oral chemotherapy: Challenges and opportunities.

Authors:  Susan Krikorian; Susan Pories; Gary Tataronis; Thomas Caughey; Kirsten Chervinsky; Margaret Lotz; Abra H Shen; Lisa Weissmann
Journal:  J Oncol Pharm Pract       Date:  2018-09-26       Impact factor: 1.809

7.  Adherence to Oral Anticancer Medications After Implementation of an Ambulatory Adherence Program at a Large Urban Academic Hospital.

Authors:  Marjorie A Curry; Iloabueke Chineke; Tyler Redelico; Constance Terrell; Winifred Bell; Darica Flood; Pooja Mishra; Jennifer LaFollette; Steve Power; Leon Bernal-Mizrachi
Journal:  JCO Oncol Pract       Date:  2020-01-21

8.  Oral chemotherapy program improves adherence and reduces medication wastage and hospital admissions.

Authors:  Nikhil Khandelwal; Ian Duncan; Tamim Ahmed; Elan Rubinstein; Cheryl Pegus
Journal:  J Natl Compr Canc Netw       Date:  2012-05       Impact factor: 11.908

9.  Impact of a pharmacist-led oral chemotherapy-monitoring program in patients with metastatic castrate-resistant prostate cancer.

Authors:  Jay M Patel; Lisa M Holle; Jessica M Clement; Thomas Bunz; Christopher Niemann; Kevin W Chamberlin
Journal:  J Oncol Pharm Pract       Date:  2015-10-22       Impact factor: 1.809

10.  2018 Hematology/Oncology Pharmacist Association Best Practices for the Management of Oral Oncolytic Therapy: Pharmacy Practice Standard.

Authors:  Emily Mackler; Eve M Segal; Benyam Muluneh; Kate Jeffers; Jenna Carmichael
Journal:  J Oncol Pract       Date:  2019-03-12       Impact factor: 3.840

View more
  1 in total

1.  ONS Guidelines™ to Support Patient Adherence to Oral Anticancer Medications.

Authors:  Sarah M Belcher; Emily Mackler; Benyam Muluneh; Pamela K Ginex; Mary K Anderson; Elizabeth Bettencourt; Ryan K DasGupta; Jennifer Elliott; Erica Hall; Michelle Karlin; Diana Kostoff; Victoria K Marshall; Vanessa E Millisor; Maegan Molnar; Susan M Schneider; Janelle Tipton; Susan Yackzan; Kristine B LeFebvre; Kapeena Sivakumaran; Haya Waseem; Rebecca L Morgan
Journal:  Oncol Nurs Forum       Date:  2022-06-17       Impact factor: 1.803

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.